What Is J147?
J147 is a synthetic neurotrophic small molecule developed through a phenotypic screening strategy built around cellular stresses associated with the aging brain. Rather than beginning with one disease protein and designing a drug around it, the research program screened for compounds capable of protecting neurons against multiple age-associated toxicities.
That distinction is central to the J147 story. Researchers first observed protective effects and then worked backward to identify the underlying biology. Subsequent work identified mitochondrial α-F1-ATP synthase (ATP5A) as a molecular target and connected J147 with calcium-dependent CAMKK2/AMPK signaling.
The Mitochondrial Connection
A 2018 study identified ATP5A as a target of J147. In experimental systems, modulation of ATP synthase increased intracellular calcium and produced sustained CAMKK2-dependent activation of the AMPK/mTOR axis. The same study reported attenuation of age-associated molecular drift in mice and lifespan extension in Drosophila.
AMPK functions as a major cellular energy sensor. This places J147 research at an intersection of mitochondrial bioenergetics, metabolism, stress responses and pathways frequently studied in aging biology. It does not establish J147 as a human longevity therapy.
Brain Aging and Alzheimer's Research
Early J147 research focused heavily on Alzheimer's disease models. Studies in aged and rapidly aging mice reported improvements in cognitive measures alongside changes in synaptic, inflammatory, vascular and metabolic markers. Multiomics work in SAMP8 mice found that J147 shifted several age- and Alzheimer's-associated molecular patterns toward a younger phenotype.
Later research also connected J147 and the related compound CMS121 with preservation of mitochondrial homeostasis and acetyl-CoA metabolism in aging mouse brain.
Neuroinflammation
A 2025 study added evidence that CAMKK2/AMPK signaling may contribute to J147's effects on inflammatory biology. In LPS-based experimental models, J147 altered microglial inflammatory behavior, changed cytokine profiles and preserved oligodendrocyte-related measures. Pharmacologic inhibition of CAMKK2 or AMPK substantially disrupted the reported protective effects.
This strengthens the mechanistic case for the pathway, but the study remained preclinical and does not demonstrate treatment of human neuroinflammatory disease.
Traumatic Brain Injury
In a 2024 controlled cortical impact study in mice, J147 was associated with reduced acute neuronal degeneration, greater long-term neuronal survival, reduced contusion volume, improved neuroplasticity and improvements across several behavioral measures. The investigators linked these findings to modulation of AMPK/SREBP-1 signaling and endoplasmic-reticulum stress.
The work expands J147 beyond the Alzheimer's field and suggests that researchers are investigating whether its cellular stress-response biology could matter after acute neurological injury. It does not establish J147 as a human TBI treatment.
Stroke and the Move Into Phase II
J147 has now entered a more consequential stage: controlled human investigation in acute ischemic stroke. The JUMPSTART study (NCT07430917) is a Phase II randomized, placebo-controlled, double-blind adaptive trial sponsored by Abrexa Pharmaceuticals.
The only earlier human study was a Phase I single-ascending-dose trial of oral J147 in healthy young and elderly volunteers (NCT03838185), completed in 2020. No results from that study have been posted or published.
The study is designed for approximately 196 adults with acute ischemic stroke and large-vessel occlusion who undergo mechanical thrombectomy. Following successful reperfusion, participants receive a single intravenous injection of J147 or placebo. Initial J147 arms use 1.6 mg/kg and 2.5 mg/kg, with subsequent dose selection built into the adaptive design.
Registry-synced records updated in August 2026 list the trial as recruiting, with an actual study start of July 22, 2026 and estimated completion in July 2028. Outcomes include safety, MRI-measured infarct volume, NIH Stroke Scale scores and 90-day modified Rankin Scale outcomes.
What J147 Is — and What It Isn't
What the evidence supports
- J147 is an experimental neuroprotective small molecule with substantial preclinical research.
- ATP5A and downstream calcium/CAMKK2/AMPK signaling are important parts of its proposed mechanism.
- Preclinical studies span aging, dementia, neuroinflammation and TBI.
- J147 has advanced into Phase II human investigation for acute ischemic stroke.
What remains unproven
- It is not an established treatment for Alzheimer's disease or TBI.
- It has not been proven to enhance focus or cognition in healthy humans.
- It has not been demonstrated to reverse human brain aging.
- It has not been demonstrated to extend human lifespan.
- Preclinical dosing should not be converted into human protocols.
The Translation Problem
J147 illustrates a recurring challenge in longevity and neuroscience research: a compound can have a fascinating mechanism, encouraging animal data and insufficient human efficacy evidence at the same time.
Neurological drug development is filled with interventions that looked compelling in experimental models but failed to deliver meaningful clinical benefits. For J147, the next decisive evidence will therefore come from well-controlled human trials—not from increasingly elaborate extrapolation of animal results.
ProtokolX Assessment
J147 is interesting not because it has been proven to make people smarter, but because it sits at the intersection of mitochondrial function, cellular energy sensing, neuroinflammation and brain aging.
The research connects mitochondrial ATP production with calcium signaling, AMPK activity, metabolic regulation and cellular stress responses. That network offers a plausible framework for the broad neuroprotective effects reported across several experimental models.
The question is no longer whether J147 can produce interesting biology. The question is whether that biology translates into meaningful human outcomes.
Research References
- Goldberg J, et al. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2018. PubMed.
- Currais A, et al. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging. 2015. PubMed.
- Currais A, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. eLife. 2019. PubMed.
- Jin R, et al. J147 treatment protects against traumatic brain injury by inhibiting neuronal endoplasmic reticulum stress potentially via the AMPK/SREBP-1 pathway. Translational Research. 2024. PubMed.
- He L, et al. J147 modulates microglial polarization via CAMKK2/AMPK signaling to ameliorate neuroinflammation. Biochem Biophys Res Commun. 2025. PubMed.
- ClinicalTrials.gov. Safety and Efficacy of J147 in Acute Ischemic Stroke (JUMPSTART), NCT07430917. Study record.
- ClinicalTrials.gov. Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147, NCT03838185. Study record.